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Abstract 
Background: Inflammation following intracerebral hemorrhage (ICH) significantly contributes to secondary brain 
damage and poor outcomes. Prostaglandin E2 (PGE2) is known to modulate neuroinflammatory responses and is 
upregulated in response to brain injury as a result of changes in inducible cyclooxygenase 2 (COX‑2) and the mem‑
brane‑bound type of PGE synthase. Inhibition of COX‑2 activity has been reported to attenuate ICH‑induced brain 
injury; however, the clinical utility of such drugs is limited due to the potential for severe side effects. Therefore, it is 
now important to search for downstream targets capable of preferentially modulating PGE2 signaling, and the four E 
prostanoid receptors, EP1‑4, which are the main targets of PGE2, remain a viable therapeutic option. We have previously 
shown that EP1 receptor deletion aggravates ICH‑induced brain injury and impairs functional recovery, thus the current 
study aimed to elaborate on these results by including a pharmacologic approach targeting the EP1 receptor.
Results: Chronic post‑treatment with the selective EP1 receptor antagonist, SC‑51089, increased lesion volume by 
30.1 ± 14.5% (p < 0.05) and treatment with the EP1 agonist, 17‑pt‑PGE2, improved neuromuscular functional recovery on 
grip strength (p < 0.01) and hanging wire (p < 0.05) behavioral testing. To begin identifying the mechanisms involved in 
EP1‑mediated neuroprotection after ICH, histology was performed to assess ferric iron content, neuroinflammation, leuko‑
cyte transendothelial migratory potential, and peripheral neutrophil and immunoglobulin infiltration. Following ICH, mice 
treated with the antagonist displayed increased ferric iron (p < 0.05) and cortical microgliosis (p < 0.05), whereas treatment 
with the agonist decreased cortical (p < 0.01) and striatal (p < 0.001) astrogliosis, leukocyte transendothelial migratory 
potential (p < 0.01), neutrophil infiltration (p < 0.05), and blood brain barrier breakdown (p < 0.05).
Conclusions: In agreement with our previous results, selective antagonism of the EP1 receptor aggravated ICH‑
induced brain injury. Furthermore, EP1 receptor agonism improved anatomical outcomes and functional recovery. 
Thus, the present data continues to reinforce a putative role for EP1 as a new and more selective therapeutic target 
for the treatment of ICH that could reduce the side effects associated with COX‑2 inhibition while still exploiting the 
beneficial effects.
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Background
Intracerebral hemorrhage (ICH) is the most debilitating 
and is associated with the highest mortality rates of 
all stroke subtypes, has no effective therapeutics, and 
represents a major public health problem [1, 2]. ICH is a 
multifaceted disorder with acute and chronic mechanisms 
of injury, including initial mechanical damage due to the 
expanding hematoma and compression of brain tissue and 
later inflammatory/oxidative processes primarily resulting 
from the presence of blood components [3–5]. Combating 
the strong neuroinflammatory cascade after ICH remains 
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a promising therapeutic target to reduce secondary 
brain damage and improve patient outcomes [4, 6, 7]. 
Neuroinflammation following brain injury is intimately 
connected to upregulation of cyclooxygenase (COX) 
enzymes, mainly the inducible isoform COX-2, coordinated 
expression of membrane-bound PGE synthase-1 
(mPGES-1), and consequent increased production of 
prostaglandins (e.g. PGE2) [8]. Prostaglandins have been 
shown to modulate outcomes in a variety of neurological 
disorders, including stroke, traumatic brain injury, epilepsy, 
Alzheimer’s disease (AD), and Parkinson’s disease (PD), 
among others [9–16]. Although selective inhibition 
of COX-2 has been reported to improve outcomes in 
many preclinical models of these neurological disorders, 
including ICH, the clinical use of these drugs is limited 
due to the potential for known severe side effects [17–21]. 
Therefore, targeting more specific downstream pathways 
of COX/mPGES-mediated prostaglandin signaling may 
reduce these deleterious side effects while still harnessing 
the already characterized positive immunomodulatory 
properties seen with COX-2 inhibition.
Prostaglandin E2 (PGE2) is a major product of COX/
PGES activity in the central nervous system and is classically 
thought of as proinflammatory within the brain [16, 22, 
23]. However, emerging evidence suggests a complex 
scenario with PGE2 capable of exerting pro- and/or anti-
inflammatory functions depending on the underlying 
neuropathophysiology [9, 11, 22, 24]. The many actions of 
PGE2 are produced by its differential stimulation of mainly 
the G-protein-coupled E prostanoid (EP) receptors 1-4, 
which display varied anatomical distributions, cellular 
expression profiles, ligand binding affinity, desensitization 
kinetics, and signal transduction pathways [25–27]. In 
the present study, we focus on the EP1 receptor, which is 
reported to be expressed in the thalamus/hypothalamus, 
hippocampus, cortex, striatum, and cerebellum [22]. EP1 
stimulation results in increased intracellular calcium 
levels via coupling to a Gαq protein, phosphatidyl inositol 
hydrolysis, and extracellular calcium influx [28, 29].
We and others have documented the pro- and/
or anti-inflammatory effects and neurotoxic or 
neuroprotective properties of signaling through the 
PGE2-EP1 axis in various models of acute and chronic 
neurological disorders such as stroke, hypoxic-ischemic 
encephalopathy (HIE), traumatic brain injury (TBI), 
AD, and PD [10, 11, 14, 15, 24, 28, 30–32]. In models 
of transient forebrain ischemia, focal ischemia, and 
excitotoxicity, PGE2-EP1 signaling aggravates brain 
damage possibly by increasing blood brain barrier 
(BBB) disruption and vascular tone and decreasing 
neuronal resistance to oxidative stress and cell death 
[24, 28, 30, 31]. Similarly, the neurotoxicity associated 
with PGE2-EP1 signaling was shown in a combined 
model of AD and cerebral ischemia, where amyloid 
plaques and neuronal damage were reduced in EP1-
deleted AD mice following ischemic insult [15]. Further, 
inhibition of EP1 with a selective antagonist reduced 
HIE cerebral injury [32]. In a model of toxin-induced 
Parkinsonism, dopaminergic neurons were protected 
and apomorphine-induced contralateral rotations were 
decreased in EP1−/− mice [14]. On the contrary, deletion 
or antagonism of the EP1 receptor failed to provide 
neuroprotection in a contusive model of TBI [10]. Last, 
we have recently shown that genetic deletion of the 
EP1 receptor aggravates ICH-induced brain injury and 
impairs functional recovery, where mechanistic evidence 
was provided to suggest EP1 stimulation positively 
modulates microglial activation and phagocytosis [11]. 
Thus, signaling through the PGE2-EP1 axis has a complex 
role following brain injury and appears to depend on the 
underlying pathologic processes, and possibly also on the 
genetic and/or pharmacologic approach used.
The present study aimed to explore our prior data in 
EP1−/− mice by extension to post-ICH pharmacologic 
manipulation of the EP1 receptor. In line with our previ-
ous results, here we show that selective antagonism of the 
EP1 receptor with SC-51089 chronically following ICH 
exacerbates brain injury and increases ferric iron deposi-
tion and microgliosis. Furthermore, repeated administra-
tion of 17-pt-PGE2, an EP1 agonist, after ICH improved 
functional recovery and reduced astrogliosis, leukocyte 
transendothelial migratory potential, peripheral neutro-
phil infiltration, and BBB breakdown.
Methods
Mice
Experiments were performed with 11–13-week-old 
C57BL/6 male mice. The colony was bred and main-
tained in our animal facilities in a temperature-controlled 
reverse light cycle environment (23  ±  2°C, 12-h light/
dark cycle) so that behavioral testing could be performed 
during the awaken phase. Mice were allowed free access 
to food and water before and after surgical procedures. 
All animal protocols were approved by the University of 
Florida Institutional Animal Care and Use Committee.
ICH model
ICH was induced by unilateral intrastriatial infusion of 
collagenase type VII-S (Sigma, St. Louis, MO, USA) as 
we have described previously [11]. Briefly, mice were 
anesthetized with isoflurane (3% induction, 1–1.5% 
maintenance) and immobilized on a stereotactic frame 
(Stoelting, Wood Dale, IL, USA). After making a small 
incision in the skin overlying the skull, a craniotomy 
was performed 0.5  mm anterior and 2.4  mm right of 
bregma. Collagenase (0.04 units in 0.2 µl of sterile saline) 
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was infused 3.2 mm ventral from the dura over a 5-min 
period using a syringe with a 26-gauge blunt tip needle 
(Hamilton Co., Reno, NV, USA). Rectal temperatures 
were maintained at 37.0 ± 0.5°C throughout all surgical 
procedures and mice were allowed to recover in tempera-
ture- and humidity-controlled chambers for at least 1 h 
postoperatively.
Experimental groups and drug treatments
Mice (n = 30) were equally distributed into three treat-
ment groups: antagonist, agonist, and control. The 
antagonist 8-chloro-2-[1-oxo-3-(4-pyridinyl)propyl]
hydrazide-dibenz[b,f ][1,4]oxazepine-10(11H)-carboxylic 
acid, monohydrochloride] (SC-51089) is selective for the 
EP1 receptor (Ki = 1260 nM) and was administered at a 
dose of 10  µg/kg of body weight. Intraperitoneal treat-
ment with this dose either 5 min or 6 h after reperfusion 
significantly reduced infarct volume and brain swell-
ing and improved neurological deficits in the transient 
middle cerebral artery occlusion stroke model [33]. The 
agonist 9-oxo-11α,15S-dihydroxy-17-phenyl-18,19,20-
trinor-prosta-5Z,13E-dien-1-oic acid (17-pt-PGE2) is 
non-selective for the EP1 receptor, with Ki values of 12.6 
and 3.7 nM for the EP1 and EP3 receptors, respectively 
[34]. The dose of 0.3  mg/kg of body weight was chosen 
based on a previous study where intravenous pretreat-
ment (10 min prior) was shown to aggravate histamine-
mediated gastric mucosal injury [35]. SC-51089 and 
17-pt-PGE2 were purchased from Cayman Chemicals 
(Ann Arbor, MI, USA). Stock solutions were prepared in 
dimethyl sulfoxide (DMSO) and subsequently aliquoted 
and stored at −20°C. Solutions for injections were freshly 
diluted from stock aliquots in sterile saline such that 
the final concentration of DMSO was only 0.001% and 
mice were appropriately rehydrated. The control group 
received an equivalent volume saline injection. Injections 
were performed subcutaneously immediately following 
surgical procedures, 6  h post-hemorrhage, and at 12-h 
intervals thereafter until the 72-h endpoint.
Neurobehavioral testing
Functional outcomes were assessed at 24, 48, and 72  h 
after ICH with the following neurobehavioral tests: grip 
strength, hanging wire task, accelerating rotarod perfor-
mance, and open field locomotor activity. For all tests, 
baseline function was assessed the day prior to surgery. 
Testing was performed during the dark cycle (awaken 
phase) by investigators blinded to treatment group. Each 
test was performed at the same time of day and mice were 
allowed 30–45 min of rest between tests. Grip strength: 
forelimb strength was measured using the Animal Grip 
Strength System (San Diego Instruments, San Diego, CA, 
USA). Mice were suspended by the tail over the testing 
grid until their forepaws had a grip on the steel bar and 
then pulled away from the grid until they released their 
grip. Five consecutive trials per mouse were performed 
for each testing period. Data are reported as the average 
maximal force recorded prior to the mouse releasing its 
hold on the bar. Hanging wire task: mice were allowed 
to grip a steel wire suspended 50 cm above a padded flat 
surface with their two forelimbs and the latency to fall 
was recorded to evaluate muscle strength and condition. 
Accelerating rotarod performance: mice were assessed 
for motor deficits and coordination, endurance, and bal-
ance using an accelerating rotarod Rotamex-5 machine 
and software (Columbus, OH, USA). Mice were trained 
on the three consecutive days prior to surgery, where 
the last training period served as baseline functioning. 
Rotational speed started at 5  rpm and ended at 50  rpm 
and the latency to fall was automatically collected by 
the Rotamex-5 software. Open field locomotor activity: 
ambulatory time was measured using an automated open 
field activity monitor and video tracking interface system 
(MED Associates, St. Albans, VT, USA). Briefly, mice 
were placed individually in four transparent acrylic cages 
and their activity was recorded over a 20-min test period. 
Data are represented as ambulatory counts omitting the 
first 5 min to exclude for initial anxiety responses.
Histological procedures and quantification
At 72  h post-ICH, mice were deeply anesthetized and 
transcardially perfused with phosphate-buffered saline 
(PBS, pH 7.4) followed by 4% paraformaldehyde (PFA). 
Brains were collected and stored in 4% PFA for at least 
24  h prior to cryopreservation in a 30% sucrose/PBS 
solution. Sections were processed at 30 µm using a Leica 
CM 1850 cryostat (Buffalo Grove, IL, USA) and stored 
at −80°C for later histological procedures. Cresyl violet 
staining was used for determination of lesion volume 
[24]. To assess ferric iron content, Perl’s iron staining 
was completed by incubating slides in a 1:1 mix of 
2% hydrochloric acid and 2% potassium ferrocyanide 
for 20  min, followed by counterstaining with nuclear 
fast red. Immunohistochemistry was performed to 
evaluate microglial activation, astrogliosis, leukocyte 
transendothelial migratory potential, neutrophil 
infiltration, and BBB breakdown using the following 
primary antibodies: ionized calcium-binding adapter 
protein 1 (Iba1), 1:1000 (Wako, Richmond, VA, USA); 
glial fibrillary acidic protein (GFAP), 1:1000 (Dako, 
Carpinteria, CA); platelet endothelial cell adhesion 
molecule 1 (PECAM-1), 1:400 (Santa Cruz, Dallas, 
TX, USA); myeloperoxidase (MPO), 1:500 (Pierce, 
Dallas, TX, USA); and immunoglobulin G (IgG), 
1:300 (Vector Laboratories, Burlingame, CA, USA), 
respectively. A secondary biotinylated antibody was 
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used for detection (Vector Laboratories), except for IgG 
staining, which used a biotinylated primary anti-mouse 
IgG antibody. The Vectastain Elite ABC kit and DAB 
kit (Vector Laboratories) were used per manufacturer’s 
instructions for the avidin-peroxidase step and final 
DAB reaction, respectively. GFAP and Iba1 slides 
were not counterstained, MPO and IgG slides were 
counterstained with Cresyl violet, and PECAM-1 slides 
were counterstained with nuclear fast red. After Cresyl 
violet, Perl’s iron, and immunohistochemical staining, 
slides were dehydrated in increasing concentrations of 
ethanol and coverslipped with Permount.
All slides were scanned using a ScanScope CS 
and analyzed with ImageScope software (Aperio 
Technologies, Inc., Vista, CA, USA). Lesion volume 
was determined by outlining of the injured areas 
on 32 sections equally distributed throughout the 
entire hematoma and anteroposterior brain regions. 
Lesion areas for each section were abstracted from 
the ImageScope software and a lesion volume was 
calculated using these areas, known distance between 
each section, and section thickness. Ferric iron content 
and immunohistochemical stains were quantified using 
the ImageScope ‘Positive Pixel Count’ algorithm after 
the appropriate brain regions were outlined (see below). 
Algorithms were tuned for each of the stains such 
that the appropriate signal and strength of signal was 
detected. As an example, moderate and strongly positive 
blue pixels are detected in Perl’s iron slides, and not 
weakly positive pixels because these could potentially 
represent non-specific signal. For each stain, the same 
four sections representing maximal lesion areas were 
used. Cortical microgliosis was analyzed by placing 
identically sized boxes of 1,500 by 1,500 pixels in the 
ipsilateral and contralateral cortex. Data are presented 
as the relative ipsilateral to contralateral signal. Striatal 
microgliosis was analyzed by outlining of the ipsilateral 
and contralateral striatum, excluding the lesion area. 
Data are presented as the ipsilateral signal per area 
quantified with normalization for the contralateral signal 
per area quantified. Cortical and striatal astrogliosis were 
analyzed in a similar manner to microgliosis; however, 
these data were not normalized due to negligible signal in 
the contralateral cortex and striatum with the thresholds 
used here. Cortical and striatal astrogliosis data are 
presented as the signal per area quantified. Perl’s, MPO, 
and PECAM-1 slides were analyzed by circling of the 
ipsilateral hemisphere. Whole brain signal was examined 
for IgG quantification because staining extended into the 
contralateral side in some cases. After all analyses, the 
appropriate algorithm was run and data was abstracted 
from the ImageScope software.
Statistical analyses
GraphPad Prism 6 software was used for all statisti-
cal analyses (San Diego, CA, USA). Differences between 
two groups were determined by an unpaired two-
tailed parametric Student’s t test. Data are expressed as 
mean ±  SEM, and p  <  0.05 was considered statistically 
significant in all comparisons.
Results
Mice were treated after ICH with the selective EP1 
receptor antagonist SC-51089 or the EP1/EP3 receptor 
agonist 17-pt-PGE2 and various anatomical and functional 
outcomes were evaluated by histological staining and 
neurobehavioral testing, respectively. Treatment with the 
antagonist resulted in a 20% mortality rate, whereas no 
mortality was seen in the agonist or control groups.
Effect of blockade or stimulation of the EP1 receptor 
on ICH‑induced brain injury
Striatal hemorrhages were reproducible in all treat-
ment groups (Fig.  1a). Quantification of lesion volumes 
ba Saline SC-51089 17-pt-PGE2
Fig. 1 Effect of blockade or stimulation of the EP1 receptor on ICH‑induced brain injury. Antagonist (SC‑51089, 10 µg/kg), agonist (17‑pt‑PGE2, 
0.3 mg/kg), or vehicle (saline) was administered subcutaneously at the onset of injury, 6 h post‑ICH, and at 12‑h intervals thereafter. Seventy‑two 
hours after ICH, brains were harvested and sections processed for Cresyl violet staining and lesion volume determination. a Representative photo‑
micrographs of coronal brain sections from control (left panel), SC‑51089‑ (middle panel), and 17‑pt‑PGE2‑ (right panel) treated mice. Scale bar 1 mm. 
b Quantification showed that SC‑51089‑treated mice had significantly more ICH‑induced brain injury, whereas no significant differences were seen 
with 17‑pt‑PGE2 treatment. *p < 0.05 when compared to the control group, n = 8–10 per group.
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showed that SC-51089-treated animals had 30.1 ± 14.5% 
larger lesions when compared to the control group 
(15.92 ±  1.67 vs. 12.35 ±  0.72  mm3, p  <  0.05; Fig.  1b), 
whereas no significant differences were seen for the 
17-pt-PGE2-treated mice.
Effect of blockade or stimulation of the EP1 receptor 
on functional outcomes
Neurobehavioral testing was performed daily follow-
ing ICH by investigators blinded to treatment group. All 
mice within the study participated in all behavioral test-
ing and no significant differences in baseline functioning 
were seen between the treatment groups on any of the 
behavioral tests employed here. The 17-pt-PGE2-treated 
mice exhibited improved neurologic function when com-
pared to the control group on two of the four behavioral 
tests performed, whereas no significant differences in 
functional recovery were seen for the SC-51089-treated 
mice (Fig.  2). Grip strength: The average baseline grip 
strength for the control and 17-pt-PGE2 groups were 
147.9 ± 3.5 and 154.4 ± 6.9 g, respectively, and these val-
ues were not statistically different. At all testing periods 
post-ICH, all treatment groups demonstrated signifi-
cantly impaired grip strength when compared to baseline 
testing (p  <  0.0001). However, at 24  h post-ICH, 17-pt-
PGE2-treated mice had significantly improved forelimb 
strength when compared to the control group (97.2 ± 4.0 
vs. 69.2 ± 9.3 g, p < 0.05; Fig. 2a). These mice continued to 
have better forelimb muscular function at 48 h (76.7 ± 4.5 
vs. 61.1 ± 3.4 g, p < 0.05; Fig. 2a) and 72 h (77.5 ± 4.2 vs. 
59.6 ±  4.0  g, p  <  0.01; Fig.  2a) post-ICH. Hanging wire 
task: mice treated with 17-pt-PGE2 were able to hang 
for longer times on a suspended wire when compared 
to the control group at 24  h after ICH (52.2  ±  12.1 vs. 
22.3 ± 4.7 s, p < 0.05; Fig. 2b). Average baseline latency to 
fall from the wire was not significantly different between 
the two groups (17-pt-PGE2: 131.3  ±  17.7  s, control: 
121.1 ±  18.5  s). There were no significant differences in 
performance on an accelerating rotarod (Fig. 2c) or open 
field locomotor activity (Fig.  2d) for the 17-pt-PGE2-
treated group. For the SC-51089-treated mice, no signifi-
cant differences in functional outcomes were seen at any 
time point post-ICH with the behavioral tests used in this 
study.
Fig. 2 Effect of blockade or stimulation of the EP1 receptor on functional outcomes after ICH. Antagonist (SC‑51089, 10 µg/kg), agonist (17‑pt‑PGE2, 
0.3 mg/kg), or vehicle (saline) was administered subcutaneously at the onset of injury, 6 h post‑ICH, and at 12‑h intervals thereafter. Neurobehavioral 
testing was performed at 24, 48, and 72 h after ICH by individuals blinded to the treatment groups. No significant differences in baseline function‑
ing were seen between the treatment groups on any of the neurobehavioral tests. a Grip strength testing showed that mice treated with 17‑pt‑
PGE2 had significantly improved forelimb strength at all testing time points post‑ICH, whereas no significant differences were seen with SC‑51089 
treatment. b Mice treated with 17‑pt‑PGE2 had significantly improved latency to fall on the hanging wire task at 24 h following ICH, whereas no 
significant differences were seen with SC‑51089 treatment. c Mice in all treatment groups displayed similar performance on an accelerating rotarod 
after ICH. d Treatment with SC‑51089 or 17‑pt‑PGE2 did not affect post‑ICH ambulatory activity. *p < 0.05 and **p < 0.01 when compared to the 
control group, n = 8–10 per group.
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Effect of blockade or stimulation of the EP1 receptor 
on brain ferric iron content
To begin analyzing the mechanisms involved in EP1-
mediated neuroprotection following ICH, Perl’s iron 
staining was performed to assess brain ferric iron con-
tent. Ferric iron predominately accumulated in peri-
hematomal regions in all treatment groups (Fig.  3a). 
Quantification revealed that SC-51089-treated ani-
mals had 251.3 ±  93.4% more ferric iron in the ipsilat-
eral hemisphere when compared to the control group 
(18.99  ±  5.05 vs. 5.41  ±  1.48  A.U., p  <  0.05; Fig.  3b), 
whereas no significant differences were seen for the 
17-pt-PGE2-treated mice. No ferric iron deposition was 
seen in the contralateral hemisphere for any of the mice 
in the study.
Effect of blockade or stimulation of the EP1 receptor 
on microglial activation and astrogliosis
To further delineate mechanisms, cortical and striatal 
microglial activation and astrogliosis were identified by 
Iba1 and GFAP immunohistochemistry, respectively. 
Following ICH, SC-51089-treated mice displayed 
more cortical microglial activation and morphological 
changes when compared to the control group, whereas 
no significant differences were seen in striatal micro-
gliosis or for the 17-pt-PGE2-treated mice. All treat-
ment groups displayed increased cortical (Fig.  4a) and 
striatal (Fig.  4b) microglial activation and morpho-
logical changes in the ipsilateral hemisphere relative 
to the contralateral equivalent areas. Quantification 
of cortical Iba1 immunoreactivity showed that SC-
51089-treated mice had 52.8 ± 16.7% more microgliosis 
when compared to the control group (3.14  ±  0.34 vs. 
2.05 ± 0.34 A.U., p < 0.05; Fig. 4c). Cortical microglio-
sis was not significantly different for the 17-pt-PGE2-
treated group (17-pt-PGE2: 2.37  ±  0.41  A.U., control: 
2.05  ±  0.34  A.U.; Fig.  4c). No significant differences 
in striatal microgliosis were seen for either treat-
ment group (SC-51089: 2.73  ±  0.34  A.U., 17-pt-PGE2: 
2.48 ± 0.20 A.U., control: 2.65 ± 0.31 A.U.; Fig. 4d).
When compared to the control group, 17-pt-PGE2-
treated mice had significantly less cortical and striatal 
astrogliosis, whereas no significant differences were 
seen with SC-51089 treatment. Similar to microgliosis, 
all treatment groups displayed significantly increased 
ipsilateral cortical (Fig.  5a) and striatal (Fig.  5b) astro-
gliosis compared to the contralateral equivalent areas. 
Quantification of GFAP immunoreactivity showed that 
17-pt-PGE2-treated mice had 38.1  ±  7.7% less cortical 
astrogliosis (0.0697  ±  0.0086  A.U. vs. 0.1126  ±  0.0089, 
p < 0.01; Fig. 5c) and 42.6 ± 7.3% less striatal astroglio-
sis (0.0616 ± 0.0079 A.U. vs. 0.1072 ± 0.0062, p < 0.001; 
Fig. 5d). No significant differences in cortical (SC-51089: 
0.0951  ±  0.0232  A.U., control: 0.1126  ±  0.0089  A.U.; 
Fig. 5c) or striatal (SC-51089: 0.0892 ± 0.0164 A.U., con-
trol: 0.1072 ± 0.0062 A.U.; Fig. 5d) astrogliosis were seen 
for the SC-51089-treated group.
Effect of blockade or stimulation of the EP1 receptor 
on leukocyte transendothelial migratory potential, 
peripheral neutrophil infiltration, and BBB breakdown
Additional immunohistochemical staining for PECAM-
1, MPO, and IgG was performed to identify leuko-
cyte transendothelial migratory potential, peripheral 
SC-51089 17-pt-PGE2Salinea b
Fig. 3 Brain ferric iron content following ICH and blockade or stimulation of the EP1 receptor. Antagonist (SC‑51089, 10 µg/kg), agonist (17‑pt‑PGE2, 
0.3 mg/kg), or vehicle (saline) was administered subcutaneously at the onset of injury, 6 h post‑ICH, and at 12‑h intervals thereafter. Seventy‑two 
hours after ICH, brains were harvested and sections processed for Perl’s staining and ferric iron content determination. a Representative high mag‑
nification photomicrographs showing ferric iron (blue) accumulation in the perihematomal regions of control (left panel), SC‑51089‑ (middle panel), 
and 17‑pt‑PGE2‑ (right panel) treated mice. Square selections in the insets denote magnified regions. Scale bars on the magnified images and insets 
are 100 µm and 1 mm, respectively. b Quantification of brain ferric iron content in the ipsilateral hemisphere showed that SC‑51089‑treated mice 
had significantly more ferric iron accumulation, whereas no significant differences were seen for the 17‑pt‑PGE2‑treated mice. No ferric iron deposi‑
tion was seen in the contralateral hemisphere for any of the mice in the study. *p < 0.05 when compared to the control group, n = 8–10 per group.
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neutrophil infiltration, and BBB breakdown, respectively. 
PECAM-1 (Fig.  6a) and MPO (Fig.  6b) staining was only 
observed within injured brain regions. IgG staining was 
diffusely present throughout the ipsilateral hemisphere 
and crossed into the contralateral hemisphere in some 
cases (Fig.  6c). Quantification showed that 17-pt-PGE2-
treated mice had 48.4  ±  6.5% less PECAM-1 immunore-
activity when compared to the control group (7.83 ± 0.98 
vs. 15.17  ±  2.18  A.U., p  <  0.01; Fig.  6d). Likewise, these 
mice also had 62.6  ±  14.7% less neutrophil infiltration 




























Fig. 4 Iba1 expression following ICH and blockade or stimulation of the EP1 receptor. Antagonist (SC‑51089, 10 µg/kg), agonist (17‑pt‑PGE2, 
0.3 mg/kg), or vehicle (saline) was administered subcutaneously at the onset of injury, 6 h post‑ICH, and at 12‑h intervals thereafter. Seventy‑two 
hours after ICH, brains were harvested and sections processed for Iba1 immunohistochemistry to evaluate cortical and striatal microgliosis. a, b 
Representative high magnification photomicrographs showing the ipsilateral and contralateral a cortex and b striatum for Iba1 immunohistochem‑
istry of coronal brain sections from control (left panels), SC‑51089‑ (middle panels), and 17‑pt‑PGE2‑ (right panels) treated mice. Square selections 
in the insets denote magnified regions. Scale bars on the magnified images and insets are 100 µm and 2 mm, respectively. c, d Quantification of 
Iba1 immunoreactivity demonstrated that SC‑51089‑treated mice had significantly more c cortical microgliosis, whereas no significant differences 
were seen in (d) striatal microgliosis. This increased cortical Iba1 immunoreactivity was accompanied by more cellular morphological changes. No 
significant differences in c cortical or d striatal microgliosis were seen for the 17‑pt‑PGE2‑treated mice. Data is normalized to the corresponding 
contralateral equivalent signal with appropriate control for the area of quantification in striatal analyses (see “Methods”). *p < 0.05 when compared 
to the control group, n = 8–10 per group.
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(1.21  ±  0.48 vs. 3.24  ±  0.67  A.U., p  <  0.05; Fig.  6e) and 
59.1 ± 11.9% less IgG immunoreactivity (0.265 ± 0.077 A.U. 
vs. 0.649 ± 0.121 A.U., p < 0.05; Fig. 6f). No significant dif-
ferences in PECAM-1, MPO, or IgG immunoreactivity were 
observed for the SC-51089-treated group.
Discussion
We have shown that chronic post-treatment with 
SC-51089, a selective EP1 receptor antagonist, aggravates 
brain injury after ICH, resulting in larger lesion vol-
umes and more iron accumulation, whereas treatment 































Fig. 5 GFAP expression following ICH and blockade or stimulation of the EP1 receptor. Antagonist (SC‑51089, 10 µg/kg), agonist (17‑pt‑PGE2, 
0.3 mg/kg), or no treatment (saline) was administered subcutaneously at the onset of injury, 6 h post‑ICH, and at 12‑h intervals thereafter. Seventy‑
two hours after ICH, brains were harvested and sections processed for GFAP immunohistochemistry to evaluate cortical and striatal astrogliosis. a, 
b Representative high magnification photomicrographs showing the ipsilateral and contralateral a cortex and b striatum for GFAP immunohisto‑
chemistry of coronal brain sections from control (left panels), SC‑51089‑ (middle panels), and 17‑pt‑PGE2‑ (right panels) treated mice. Square selections 
in the insets denote magnified regions. Scale bars on the magnified images and inserts are 100 µm and 2 mm, respectively. c, d Quantification of 
GFAP immunoreactivity demonstrated that 17‑pt‑PGE2‑treated mice had significantly less c cortical and d striatal astrogliosis, whereas no significant 
differences were seen for SC‑51089‑treated mice. All treatment groups demonstrated negligible staining in the contralateral cortex and striatum; 
thus, data is presented as the ipsilateral GFAP immunoreactivity corrected for the area of quantification, without normalization for the contralateral 
equivalent areas. **p < 0.01 and ***p < 0.001 when compared to the control group, n = 8–10 per group.
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EP3 receptor agonism, results in no detectable changes 
in lesion volume or iron deposition, but improves neu-
romuscular functional recovery. The two treatments 
resulted in differential patterns of microglial and astro-
cyte activation, with EP1 antagonism producing increased 
cortical microgliosis and EP1/EP3 agonism (later referred 
to as EP1 agonism or EP1 agonist) resulting in reduced 
cortical and striatal astrogliosis. Last, treatment with the 
EP1 agonist reduced leukocyte transendothelial migratory 
potential, neutrophil infiltration, and BBB breakdown.
Our results demonstrating that post-ICH EP1 
antagonism exacerbates brain injury are in agreement 
with our previous study that showed significantly more 
ICH-induced brain injury and worse functional outcomes 
in mice with genetic deletion of the EP1 receptor [11], 
although we did not observe smaller lesion volumes 
with the EP1 agonist used in this study, 17-pt-PGE2. 
This EP1 agonist has Ki values of 12.6 and 3.7 nM for the 
EP1 and EP3 receptors [34], respectively, and the non-
selective nature could have led to the outcomes seen 
here. In support of this hypothesis, we have recently 
shown that EP3−/− mice have less ICH-induced brain 
injury when compared to WT controls, implying an 












Fig. 6 PECAM‑1, MPO, and IgG immunoreactivity following ICH and blockade or stimulation of the EP1 receptor. Antagonist (SC‑51089, 10 µg/kg), 
agonist (17‑pt‑PGE2, 0.3 mg/kg), or vehicle (saline) was administered subcutaneously at the onset of injury, 6 h post‑ICH, and at 12‑h intervals there‑
after. Seventy‑two hours after ICH, brains were harvested and sections processed for PECAM‑1, MPO, and IgG immunohistochemistry to evaluate 
leukocyte transendothelial migratory potential, neutrophil infiltration, and BBB breakdown, respectively. a, b, c Representative high magnification 
photomicrographs showing a PECAM‑1 staining highlighting blood vessels within the lesion, b MPO‑positive neutrophils within the lesion, and c 
IgG staining within the lesion and surrounding areas of coronal brain sections from control (left panels), SC‑51089‑ (middle panels), and 17‑pt‑PGE2‑ 
(right panels) treated mice. Square selections in the insets denote magnified regions. Scale bars on the magnified images and inserts are 100 µm and 
2 mm, respectively. d, e, f Quantification revealed that 17‑pt‑PGE2‑treated mice had significantly less d PECAM‑1 staining, e neutrophil infiltration, 
and f BBB breakdown. All quantification data are presented at the same scale such that the relative d PECAM‑1, e MPO, and f IgG immunoreactiv‑
ity can be directly compared. No significant differences were seen for the SC‑51089‑treated mice. *p < 0.05 and **p < 0.01 when compared to the 
control group, n = 7–10 per group.
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to the neuroprotective effects of the EP1 receptor [36]. 
Therefore, it is likely that the overall desired beneficial 
effect of 17-pt-PGE2 by agonism of the EP1 receptor is 
negated by simultaneous EP3 receptor agonism, resulting 
in no observed differences with 17-pt-PGE2 treatment 
when compared to the control group. It is also possible 
that the dose used here for agonist treatment (selected 
based on previous systemic studies and not in the context 
of stroke) may not be high enough to affect lesion volume 
after ICH. Interestingly, the 17-pt-PGE2-treated mice 
performed better on neurobehavioral testing, including 
grip strength examination and the hanging wire task. 
In our aforementioned observations with EP3−/− 
mice, we did not find the same extent of differences on 
neurobehavioral testing as compared to EP1−/− mice, 
and thus collectively these data imply an important role 
for the PGE2-EP1 signaling axis in post-ICH functional 
recovery. Additional studies with 17-pt-PGE2 treatment 
in the appropriate EP receptor knockout animals would 
be necessary to verify this suggestion. Furthermore, 
studies in other ICH models and using additional 
selective EP1 receptor agonists, with a dose-response 
curve and multiple endpoints, will clarify the therapeutic 
potential of targeting the EP1 receptor for the treatment 
of ICH. Nevertheless, the main finding that post-
treatment with a selective EP1 antagonist aggravates 
ICH-induced brain injury supports our previous findings 
suggesting an important role for the EP1 receptor in 
positively modulating ICH outcomes. Many studies 
have shown differential effects of modulating PGE2-EP1 
receptor signaling on outcomes in models of acute and 
chronic neurologic disorders [10, 11, 14, 15, 24, 28, 
31, 32], including contradictory results in the various 
stroke models. It appears that EP1 receptor agonism 
and antagonism may be useful under hemorrhagic and 
ischemic conditions, respectively [11, 24, 33].
Hemolysis following ICH is an important trigger in 
the progression of brain injury. The liberated free heme 
generates ferric ions (Fe3+), which via the Fenton reaction 
produce reactive oxygen species, inducing oxidative 
stress. To understand whether EP1 receptor activation or 
inhibition modulates ferric iron content, brain sections 
were subjected to Perl’s iron staining. Analogous to the 
effects seen with SC-51089 and 17-pt-PGE2 treatment 
on lesion volume, we found an increase in the ferric iron 
content of antagonist-treated mice, while no significant 
differences were observed in the agonist-treated group. 
These data suggest that inhibition of PGE2-EP1 receptor 
signaling prevents the clearance of iron from injured 
brain regions, which may be a consequence of impaired 
microglial phagocytosis with EP1 blockade since deletion 
of this receptor has been reported to reduce phagocytic 
capability [11]. However, another possible explanation 
is that antagonist-treated mice have more bleeding, 
leading to more accumulation of iron in the hemorrhagic 
area. The latter hypothesis is supported by our previous 
findings indicating that deletion of the EP1 receptor 
increases cerebral blood flow [28].
Microglial and astrocyte activation is another 
criterion to gauge injury severity and monitor the 
neuroinflammatory response. Following ICH, microglia 
likely play a dual role where they are protective in their 
cleanup of red blood cells and damaged brain tissue, 
thereby promoting repair, but toxic in their facilitation 
of neuroinflammation and recruitment of leukocytes 
through the production of proinflammatory cytokines [11, 
37]. Here, significantly increased microgliosis was seen in 
ipsilateral cortical regions with EP1 antagonist treatment, 
whereas no differences were seen in the ipsilateral striatal 
regions of the same group or in the agonist-treated 
group. We have previously shown that the EP1 receptor 
colocalizes with microglial markers in perihematomal 
regions and that receptor deletion reduces the activated 
microglial population and phagocytic function [11]. 
Several possibilities exist to explain these contradictory 
striatal microgliosis findings in EP1−/− mice and WT mice 
treated with an EP1 antagonist: (1) prostaglandin receptors 
are reported to cross talk [38], and it is possible that EP1 
deletion caused the expression of another prostanoid 
receptor important for regulating microglial activation 
state to change, (2) deletion of the EP1 receptor reduces 
basal levels of microglial activation, and (3) EP1−/− mice 
may develop some other compensatory mechanism. 
In comparing cortical and striatal post-ICH microglial 
activation state with EP1 antagonism, cortical microglia 
appear to retain their ability to activate and respond to the 
injury, indicating a brain region-specific response.
Astrocytes play diverse roles in response to brain 
injury, where they try to contain the damage be forming 
a glial scar [39, 40]. However, excessive or sustained 
astrocyte activation can be detrimental and augment 
brain damage and functional deficits by contributing to 
chronic inflammation and cell death. Treatment with 
the antagonist had no effect on astrogliosis, whereas the 
agonist significantly reduced astrogliosis in the ipsilateral 
cortical and striatal regions. Strong evidence exists 
suggesting that impairment of astrogliosis improves 
axonal growth and improves functional outcomes 
following brain injury [41, 42]. Here, we observed a 
significant decrease in cortical and striatal astrogliosis 
in the agonist-treated group, whereas no significant 
differences were seen with EP1 antagonist treatment. 
Intriguingly, this reduced astrogliosis with 17-pt-PGE2 
treatment was accompanied by better neuromuscular 
functional recovery. The discrepancy in astrocyte and 
microglial activation with EP1 antagonism or agonism 
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(e.g. agonism decreases astrogliosis, whereas antagonism 
does not have an effect) may also result from the 
unbalanced influence of PGE2-EP3 receptor signaling 
between the treatment groups.
Finally, we evaluated leukocyte transendothelial 
migratory potential, leukocyte infiltration, and BBB 
disruption, where we found less immunoreactivity for 
markers of these outcome measures in the agonist-treated 
group and no significant differences with EP1 antagonism. 
As previously mentioned in the context of lesion volume, 
neurobehavioral testing, and gliosis, the interpretation 
of these data is complicated given the lack of opposing 
results between the two treatment groups and non-
selective nature of the agonist toward EP1/EP3 receptors; 
although, it does suggest that the EP3 receptor may play a 
larger role in modulating these particular outcomes when 
compared to the contribution of PGE2-EP1 signaling. 
ICH initially directly disrupts the BBB, leading to a 
massive neuroinflammatory cascade that is characterized 
by invasion of the lesion cite by leukocytes and further 
damage to the vasculature. There are various triggers 
that can lead to secondary BBB dysfunction after ICH. 
Importantly, blood products (e.g. thrombin, hemoglobin, 
iron) and the inflammatory response, including that 
mediated by endogenous and infiltrating cells, play a 
critical role in ICH-induced BBB dysfunction [3, 4]. As 
previously mentioned, we found that treatment with 
the EP1 antagonist increased brain ferric iron content, 
whereas the EP1 agonist had no effect. Higher iron load 
after ICH means a greater potential for oxidative damage 
and inflammation, ultimately leading to more BBB 
damage. However, we did not observe an increase in BBB 
dysfunction in the antagonist-treated group; instead, we 
observed improved BBB integrity (as identified by IgG 
staining) in the agonist-treated mice that did not display 
less ferric iron content or smaller lesion volumes (i.e. less 
hemoglobin and thrombin). These findings suggest that in 
the present study, cell-mediated inflammatory responses 
may be primarily responsible for the observed differences 
in BBB integrity between the treatment groups.
Endogenous cell types such as microglia and astrocytes 
can secrete factors that modulate BBB permeability, 
especially with excessive or sustained activation. Here, we 
have shown that agonist-treated mice display significantly 
reduced activation of one of the key cell types responsible 
for maintenance of the BBB, astrocytes, and this reduced 
astrogliosis could be contributing to the overall preservation 
of BBB integrity with 17-pt-PGE2 treatment. However, 
infiltrating leukocytes such as neutrophils migrate to the 
site of injury and augment the neuroinflammatory cascade, 
causing further damage to the BBB. Our findings show 
that treatment with 17-pt-PGE2 decreases neutrophil 
infiltration, as monitored by immunohistochemical 
staining for MPO. In the current experimental setting, it 
is not possible to distinguish the respective contribution 
of astrogliosis and leukocyte infiltration in modulating 
BBB integrity, although both processes seem to play a role. 
Leukocytes cross the endothelium using paracellular and 
transcellular pathways [43–45]. PECAM-1 is expressed 
on the surface of several types of leukocytes (including 
neutrophils) and lateral borders of endothelial cells, and 
is involved in the transmigration phase of leukocyte 
emigration through homophilic interactions [46, 47]. 
Neutrophil transmigration capability, as tested by 
PECAM-1 staining, was found to be lower in mice treated 
with 17-pt-PGE2, implying that EP1/EP3 agonism preserves 
the BBB barrier and reduces leukocyte infiltration by 
sealing intercellular gaps between endothelial cells, and 
probably more importantly, decreasing the engagement of 
migrating leukocytes.
Conclusions
In this study we have provided additional evidence 
consistent with our previous findings suggesting a 
neuroprotective role for the EP1 receptor following ICH. 
Our results show that blockade of the PGE2-EP1 signaling 
axis aggravates ICH-induced brain injury and increases 
ferric iron deposition and microgliosis, whereas stimulation 
decreases astrogliosis, leukocyte transendothelial migratory 
potential, neutrophil infiltration, and BBB breakdown and 
improves neuromuscular functional recovery. Caution 
should be used when interpreting and extrapolating these 
results because it is likely that a portion of the findings 
are due to activation of EP3 signaling rather than EP1, 
given the non-selective nature of the agonist used in this 
study. Even so, EP1-mediated post-ICH neuroprotection 
is probably achieved by positive modulation of microglial 
phagocytosis and/or decreased bleeding tendency, leading 
to lower iron overload, less oxidative processes, and 
attenuated neuroinflammatory responses. Additional 
studies with other ICH models, a selective EP1 agonist, 
and pharmacologic manipulation of the EP3 receptor will 
clarify the respective role of these PGE2-mediated signaling 
axes after ICH. Nonetheless, the EP1 receptor remains a 
viable therapeutic target for the treatment of ICH.
Abbreviations
ABC: avidin/biotin enzyme complex; AD: Alzheimer’s disease; BBB: blood 
brain barrier; cAMP: cyclic adenosine monophosphate; COX: cyclooxygenase; 
DAB: 3,3′‑diaminobenzidine; DMSO: dimethyl sulfoxide; EP1: E prostanoid 
receptor subtype 1; EP3: E prostanoid receptor subtype 3; EP1‑/−: EP1 
receptor knockout; GFAP: glial fibrillary acidic protein; HIE: hypoxic‑ischemic 
encephalopathy; Iba1: ionized calcium‑binding adapter protein 1; ICH: 
intracerebral hemorrhage; IgG: immunoglobulin G; mPGES: membrane‑bound 
PGE synthase; MPO: myeloperoxidase; PBS: phosphate‑buffered saline; PD: 
Parkinson’s disease; PECAM‑1: platelet endothelial cell adhesion molecule 1; 
PFA: paraformaldehyde; PGE2: prostaglandin E2; SEM: standard error of the 
mean; TBI: traumatic brain injury; WT: wildtype.
Page 12 of 13Leclerc et al. BMC Neurosci  (2015) 16:48 
Authors’ contributions
JLL, ASS, and SD designed the study, interpreted results, and wrote the manu‑
script. JLL coordinated histology and blinded quantification, and analyzed 
data; NS performed surgical procedures, coordinated blinded behavioral 
testing, and assisted with histology; LS performed behavioral analyses; LS, EG, 
and AD contributed to histological staining, quantification, and data analysis. 
All authors read and approved the final manuscript.
Author details
1 Department of Anesthesiology, University of Florida, Gainesville, FL, USA. 
2 Department of Neuroscience, University of Florida, Gainesville, FL, USA. 
3 Departments of Neurology, Psychiatry, Psychology and Pharmaceutics, 
University of Florida, Gainesville, FL, USA. 4 University of Florida College 
of Medicine, 1275 Center Drive, Gainesville, FL 32610‑0159, USA. 
Acknowledgements
This work was supported by grants from the National Institutes of Health 
R01NS046400 (SD) and F31NS086441 (JL). Special thanks to David Tyburski 
for assistance with behavioral testing and to all members of the Doré lab for 
helpful discussions and technical support.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 13 January 2015   Accepted: 13 July 2015
References
 1. Broderick JP, Adams HP Jr, Barsan W, Feinberg W, Feldmann E, Grotta J 
et al (1999) Guidelines for the management of spontaneous intracerebral 
hemorrhage: a statement for healthcare professionals from a special 
writing group of the Stroke Council, American Heart Association. Stroke J 
Cereb Circ 30(4):905–915
 2. Qureshi AI, Mendelow AD, Hanley DF (2009) Intracerebral haemorrhage. 
Lancet 373(9675):1632–1644
 3. Hua Y, Keep RF, Hoff JT, Xi G (2007) Brain injury after intracerebral 
hemorrhage: the role of thrombin and iron. Stroke J Cereb Circ 38(2 
Suppl):759–762
 4. Wang J, Doré S (2007) Inflammation after intracerebral hemorrhage. 
J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 
27(5):894–908
 5. Leclerc JL, Lampert AS, Diller MA, Immergluck JB, Dore S (2015) Prosta‑
glandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage‑
induced brain injury and improves functional recovery. ASN neuro 7(2). 
doi:10.1177/1759091415578713
 6. Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ et al (2014) Fingolimod for the 
treatment of intracerebral hemorrhage: a 2‑arm proof‑of‑concept study. 
JAMA Neurol 71(9):1092–1101
 7. Peeling J, Yan HJ, Corbett D, Xue M, Del Bigio MR (2001) Effect of FK‑506 
on inflammation and behavioral outcome following intracerebral hemor‑
rhage in rat. Exp Neurol 167(2):341–347
 8. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F 
et al (2000) Regulation of prostaglandin E2 biosynthesis by inducible 
membrane‑associated prostaglandin E2 synthase that acts in concert 
with cyclooxygenase‑2. J Biol Chem 275(42):32783–32792
 9. Glushakov AV, Robbins SW, Bracy CL, Narumiya S, Doré S (2013) Pros‑
taglandin F2alpha FP receptor antagonist improves outcomes after 
experimental traumatic brain injury. J Neuroinflam 10:132
 10. Glushakov AV, Fazal JA, Narumiya S, Dore S (2014) Role of the Prostaglan‑
din E2 EP1 Receptor in Traumatic Brain Injury. PLoS One 9(11):e113689
 11. Singh N, Ma B, Leonardo CC, Ahmad AS, Narumiya S, Doré S (2013) Role 
of PGE(2) EP1 receptor in intracerebral hemorrhage‑induced brain injury. 
Neurotox Res 24(4):549–559
 12. Ahmad AS, Ahmad M, de Brum‑Fernandes AJ, Doré S (2005) Prostaglan‑
din EP4 receptor agonist protects against acute neurotoxicity. Brain Res 
1066(1–2):71–77
 13. Saleem S, Kim YT, Maruyama T, Narumiya S, Doré S (2009) Reduced acute 
brain injury in PGE2 EP3 receptor‑deficient mice after cerebral ischemia. J 
Neuroimmunol 208(1–2):87–93
 14. Ahmad AS, Maruyama T, Narumiya S, Dore S (2013) PGE2 EP1 receptor 
deletion attenuates 6‑OHDA‑induced Parkinsonism in mice: old switch, 
new target. Neurotox Res 23(3):260–266
 15. Zhen G, Kim YT, Li RC, Yocum J, Kapoor N, Langer J et al (2012) PGE2 
EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral 
ischemia and Alzheimer’s disease. Neurobiol Aging 33(9):2215–2219
 16. Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R (2013) 
Inhibition of the prostaglandin receptor EP2 following status epilepticus 
reduces delayed mortality and brain inflammation. Proc Natl Acad Sci 
USA 110(9):3591–3596
 17. Chu K, Jeong SW, Jung KH, Han SY, Lee ST, Kim M et al (2004) Celecoxib 
induces functional recovery after intracerebral hemorrhage with reduc‑
tion of brain edema and perihematomal cell death. J Cereb Blood Flow 
Metab Off J Int Soc Cereb Blood Flow Metab 24(8):926–933
 18. Sinn DI, Lee ST, Chu K, Jung KH, Song EC, Kim JM, Park DK, Kim M, Roh JK 
(2007) Combined neuroprotective effects of celecoxib and memantine in 
experimental intracerebral hemorrhage. Neurosci Lett 411(3):238–242
 19. Rojas A, Jiang J, Ganesh T, Yang MS, Lelutiu N, Gueorguieva P, Dingledine 
R (2014) Cyclooxygenase‑2 in epilepsy. Epilepsia 55(1):17–25
 20. Polascheck N, Bankstahl M, Loscher W (2010) The COX‑2 inhibitor 
parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine 
model of temporal lobe epilepsy. Exp Neurol 224(1):219–233
 21. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S et al (2003) Cycloox‑
ygenase‑2 is instrumental in Parkinson’s disease neurodegeneration. Proc 
Natl Acad Sci USA 100(9):5473–5478
 22. Andreasson K (2010) Emerging roles of PGE2 receptors in models of 
neurological disease. Prostaglandins Other Lipid Mediat 91(3–4):104–112
 23. Mohan S, Ahmad AS, Glushakov AV, Chambers C, Dore S (2012) Putative 
role of prostaglandin receptor in intracerebral hemorrhage. Front Neurol 
3:145
 24. Ahmad AS, Saleem S, Ahmad M, Doré S (2006) Prostaglandin EP1 recep‑
tor contributes to excitotoxicity and focal ischemic brain damage. Toxicol 
Sci 89(1):265–270
 25. Candelario‑Jalil E, Slawik H, Ridelis I, Waschbisch A, Akundi RS, Hull M et al 
(2005) Regional distribution of the prostaglandin E2 receptor EP1 in the 
rat brain: accumulation in purkinje cells of the cerebellum. J Mol Neurosci 
27(3):303–310
 26. Andreasson K (2010) Prostaglandin signalling in cerebral ischaemia. Br J 
Pharmacol 160(4):844–846
 27. Sugimoto Y, Narumiya S, Ichikawa A (2000) Distribution and function 
of prostanoid receptors: studies from knockout mice. Prog Lipid Res 
39(4):289–314
 28. Saleem S, Li RC, Wei G, Doré S (2007) Effects of EP1 receptor on cerebral 
blood flow in the middle cerebral artery occlusion model of stroke in 
mice. J Neurosci Res 85(11):2433–2440
 29. Katoh H, Watabe A, Sugimoto Y, Ichikawa A, Negishi M (1995) Characteri‑
zation of the signal transduction of prostaglandin E receptor EP1 subtype 
in cDNA‑transfected Chinese hamster ovary cells. Biochim Biophys Acta 
1244(1):41–48
 30. Shimamura M, Zhou P, Casolla B, Qian L, Capone C, Kurinami H et al 
(2013) Prostaglandin E2 type 1 receptors contribute to neuronal apopto‑
sis after transient forebrain ischemia. Journal Cereb Blood Flow Metab Off 
J Int Soc Cereb Blood Flow Metab 33(8):1207–1214
 31. Fukumoto K, Takagi N, Yamamoto R, Moriyama Y, Takeo S, Tanonaka K 
(2010) Prostanoid EP1 receptor antagonist reduces blood‑brain barrier 
leakage after cerebral ischemia. Eur J Pharmacol 640(1–3):82–86
 32. Taniguchi H, Anacker C, Suarez‑Mier GB, Wang Q, Andreasson K (2011) 
Function of prostaglandin E2 EP receptors in the acute outcome of 
rodent hypoxic ischemic encephalopathy. Neurosci Lett 504(3):185–190
 33. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA et al (2006) Prosta‑
glandin E2 EP1 receptors: downstream effectors of COX‑2 neurotoxicity. 
Nat Med 12(2):225–229
 34. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S 
(1997) Ligand binding specificities of the eight types and subtypes of the 
mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br 
J Pharmacol 122(2):217–224
Page 13 of 13Leclerc et al. BMC Neurosci  (2015) 16:48 
 35. Hase S, Yokota A, Nakagiri A, Takeuchi K (2003) Prostaglandin E2 aggra‑
vates gastric mucosal injury induced by histamine in rats through EP1 
receptors. Life Sci 74(5):629–641
 36. Leclerc JL, Lampert AS, Diller MA, Dore S (2015) Genetic deletion of the 
prostaglandin E2 E prostanoid receptor subtype 3 improves anatomical 
and functional outcomes after intracerebral hemorrhage. Eur J Neurosci 
41(10):1381–1391
 37. Taylor RA, Sansing LH (2013) Microglial responses after ischemic stroke 
and intracerebral hemorrhage. Clin Develop Immunol 2013:746068
 38. Kelley‑Hickie LP, Kinsella BT (2004) EP1‑ and FP‑mediated cross‑desen‑
sitization of the alpha (alpha) and beta (beta) isoforms of the human 
thromboxane A2 receptor. Br J Pharmacol 142(1):203–221
 39. Zhang Y, Barres BA (2010) Astrocyte heterogeneity: an underappreciated 
topic in neurobiology. Curr Opin Neurobiol 20(5):588–594
 40. Kang W, Hebert JM (2011) Signaling pathways in reactive astrocytes, a 
genetic perspective. Mol Neurobiol 43(3):147–154
 41. Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen 
CN et al (1999) Leukocyte infiltration, neuronal degeneration, and neurite 
outgrowth after ablation of scar‑forming, reactive astrocytes in adult 
transgenic mice. Neuron 23(2):297–308
 42. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV 
(2004) Reactive astrocytes protect tissue and preserve function after 
spinal cord injury. J Neurosci Off J Soc Neurosci 24(9):2143–2155
 43. Muller WA (2001) Migration of leukocytes across endothelial junctions: 
some concepts and controversies. Microcirculation 8(3):181–193
 44. Muller WA (2011) Mechanisms of leukocyte transendothelial migration. 
Ann Rev Pathol 6:323–344
 45. Carman CV, Springer TA (2008) Trans‑cellular migration: cell‑cell contacts 
get intimate. Curr Opin Cell Biol 20(5):533–540
 46. Muller WA (1995) The role of PECAM‑1 (CD31) in leukocyte emigration: 
studies in vitro and in vivo. J Leukoc Biol 57(4):523–528
 47. Winger RC, Koblinski JE, Kanda T, Ransohoff RM, Muller WA (2014) Rapid 
remodeling of tight junctions during paracellular diapedesis in a human 
model of the blood‑brain barrier. J Immunol 193(5):2427–2437
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
